Dorota Kustrzycka-Kratochwil

Publications (5)43.03 Total impact

• Article: [Early bioprosthetic mitral valve thrombosis].

  Michał Tkaczyszyn, Tomasz Olbrycht, Dorota Kustrzycka Kratochwil, Mateusz Sokolski, Małgorzata Sukiennik Kujawa, Jacek Skiba, Marek Gemel, Waldemar Banasiak, Ewa A Jankowska, Piotr Ponikowski
  [show abstract] [hide abstract]
  ABSTRACT: We present a case of a 70 year-old woman operated due to severe mitral regurgitation. Early after surgery transthoracic echocardiography revealed the decreased effective orifice area of the implanted bioprosthetic valve and the stenotic features of transvalvular flow. Transesophageal echocardiography (TEE) disclosed a thrombotic cause of heterograft dysfunction. Due to the clinical deterioration and the unclear cause of prosthesis stenosis, the patient was reoperated. Intra-operatively bioprosthetic mitral valve thrombosis was confirmed. Precipitating factors of this rare complication including cardiac device related infective endocarditis (CDRIE) and the diagnostic applicability of TEE in this clinical scenario are discussed.
  Kardiologia polska 01/2012; 70(2):165-8. · 0.51 Impact Factor
• Article: [Differentiation between vegetation and lead associated thrombus - role of PET scan in difficult diagnostic process].

  Piotr Niewiński, Ewa A Jankowska, Aldona Cwynar, Katarzyna Wojtas, Dorota Kustrzycka-Kratochwil, Zofia Barg, Waldemar Banasiak, Piotr Ponikowski
  [show abstract] [hide abstract]
  ABSTRACT: We report a case of a 59 year-old man with hypertrophic cardiomyopathy who developed a pathological structure attached to the lead of cardioverter-defibrillator that has been detected by echocardiography. The authors describe a difficult differential diagnostic process aiming at the differentiation between cardiac device-related infective endocarditis and lead-associated thrombus. Imaging of the heart with a pathological structure using PET scan seems to be useful in these clinical circumstances.
  Kardiologia polska 07/2010; 68(7):797-801. · 0.51 Impact Factor
• Article: Circulating estradiol and mortality in men with systolic chronic heart failure.

  Ewa A Jankowska, Piotr Rozentryt, Beata Ponikowska, Oliver Hartmann, Dorota Kustrzycka-Kratochwil, Krzysztof Reczuch, Jolanta Nowak, Ludmila Borodulin-Nadzieja, Lech Polonski, Waldemar Banasiak, Philip A Poole-Wilson, Stefan D Anker, Piotr Ponikowski
  [show abstract] [hide abstract]
  ABSTRACT: Androgen deficiency is common in men with chronic heart failure (HF) and is associated with increased morbidity and mortality. Estrogens are formed by the aromatization of androgens; therefore, abnormal estrogen metabolism would be anticipated in HF. To examine the relationship between serum concentration of estradiol and mortality in men with chronic HF and reduced left ventricular ejection fraction (LVEF). A prospective observational study at 2 tertiary cardiology centers (Wroclaw and Zabrze, Poland) of 501 men (mean [SD] age, 58 [12] years) with chronic HF, LVEF of 28% (SD, 8%), and New York Heart Association [NYHA] classes 1, 2, 3, and 4 of 52, 231, 181, and 37, respectively, who were recruited between January 1, 2002, and May 31, 2006. Cohort was divided into quintiles of serum estradiol (quintile 1, < 12.90 pg/mL; quintile 2, 12.90-21.79 pg/mL; quintile 3, 21.80-30.11 pg/mL; quintile 4, 30.12-37.39 pg/mL; and quintile 5, > or = 37.40 pg/mL). Quintile 3 was considered prospectively as the reference group. Serum concentrations of estradiol and androgens (total testosterone and dehydroepiandrosterone sulfate [DHEA-S]) were measured using immunoassays. Among 501 men with chronic HF, 171 deaths (34%) occurred during the 3-year follow-up. Compared with quintile 3, men in the lowest and highest estradiol quintiles had increased mortality (adjusted hazard ratio [HR], 4.17; 95% confidence interval [CI], 2.33-7.45 and HR, 2.33; 95% CI, 1.30-4.18; respectively; P < .001). These 2 quintiles had different clinical characteristics (quintile 1: increased serum total testosterone, decreased serum DHEA-S, advanced NYHA class, impaired renal function, and decreased total fat tissue mass; and quintile 5: increased serum bilirubin and liver enzymes, and decreased serum sodium; all P < .05 vs quintile 3). For increasing estradiol quintiles, 3-year survival rates adjusted for clinical variables and androgens were 44.6% (95% CI, 24.4%-63.0%), 65.8% (95% CI, 47.3%-79.2%), 82.4% (95% CI, 69.4%-90.2%), 79.0% (95% CI, 65.5%-87.6%), and 63.6% (95% CI, 46.6%-76.5%); respectively (P < .001). Among men with chronic HF and reduced LVEF, high and low concentrations of estradiol compared with the middle quintile of estradiol are related to an increased mortality.
  JAMA The Journal of the American Medical Association 05/2009; 301(18):1892-901. · 30.03 Impact Factor
• Article: Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants.

  Ewa A Jankowska, Justyna Jakubaszko, Aldona Cwynar, Jacek Majda, Beata Ponikowska, Dorota Kustrzycka-Kratochwil, Krzysztof Reczuch, Ludmila Borodulin-Nadzieja, Waldemar Banasiak, Philip A Poole-Wilson, Piotr Ponikowski
  [show abstract] [hide abstract]
  ABSTRACT: Bone status has not been comprehensively studied in chronic heart failure (CHF). In CHF men, we evaluated bone status, bone loss over time, and their clinical and hormonal determinants. Bone mineral content (BMC) and bone mineral density (BMD) of arms, legs, trunk, and total body were examined using dual-energy X-ray absorptiometry in 187 men with CHF [age: 60+/-11 years, left ventricular ejection fraction (LVEF): 32+/-7%, New York Heart Association (NYHA) class (I/II/III/IV): 20/76/76/15] and in 21 age-matched male controls without CHF. Men with CHF had reduced BMD and BMC compared with controls (P < 0.05). Reduced BMD and BMC were independently determined by CHF severity (high NYHA class and impaired LVEF), reduced lean tissue mass, low serum dehydroepiandrosterone sulphate, total testosterone (TT), and estimated free testosterone (eFT) (all P < 0.05). Bone status was reassessed in 60 patients who survived >2 years from the initial evaluation. Significant bone loss over time (a reduction in BMC total > or = 1%/year) occurred in 35% of CHF men. Advanced NYHA class (P < 0.05) and reduced serum TT and eFT (P < 0.0001) at baseline predicted augmented bone loss. In CHF men, reduced BMD and BMC constitute an element of generalized body wasting, determined mainly by advanced heart failure and androgen deficiencies. Significant bone loss over time frequently occurs in CHF men and is related to testosterone depletion and disease severity.
  European Journal of Heart Failure 01/2009; 11(1):28-38. · 4.90 Impact Factor
• Article: The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure.

  Ewa A Jankowska, Kinga Wegrzynowska, Malgorzata Superlak, Katarzyna Nowakowska, Malgorzata Lazorczyk, Bartosz Biel, Dorota Kustrzycka-Kratochwil, Katarzyna Piotrowska, Waldemar Banasiak, Marek Wozniewski, Piotr Ponikowski
  [show abstract] [hide abstract]
  ABSTRACT: Abnormalities in the skeletal musculature underlie exercise intolerance in chronic heart failure (CHF). We investigated, whether in CHF selective resistance training without accompanying aerobic regime favourably affects muscle strength, muscle mass and improves exercise capacity. Ten patients with stable ischaemic CHF in NYHA class III (9 men, age: 70+/-6 years [mean+/-SD], left ventricular ejection fraction: 30+/-5%, peak oxygen consumption [peak VO(2)]: 12.4+/-3.0 mL/min/kg) underwent the rehabilitation programme which consisted of a 12-week training phase (progressive resistance exercises restricted to the quadriceps muscles) followed by a 12-week detraining phase. All subjects completed a training phase of the programme with no adverse events. Resistance training markedly increased quadriceps strength (right leg: 260+/-34 vs. 352+/-28 N, left leg: 264+/-38 vs. 342+/-30 N, both p<0.01 - all comparisons: baseline vs. after training), but did not affect lean tissue mass of lower extremities (both p>0.2). It was accompanied by an improvement in clinical status (all NYHA III vs. all NYHA II, p<0.01), quality of life (Minnesota questionnaire: 44+/-15 vs. 33+/-18 points, p<0.05), exercise capacity assessed using a distance during 6-minute walk test (6MWT: 362+/-83 vs. 455+/-71 m, p<0.01), but not peak VO(2) (p>0.2). Plasma NT-proBNP remained unchanged during the training. At the end of detraining phase, only a partial improvement in quadriceps strength (p<0.05), a 6MWT distance (p<0.05) and NYHA class (p=0.07 vs. baseline) persisted. Applied resistance quadriceps training is safe in patients with CHF. It increases muscle strength, improves clinical status, exercise capacity, and quality of life.
  International journal of cardiology 12/2007; 130(1):36-43. · 7.08 Impact Factor